Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast cancer drug for ...

The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand name Veppanu. Accordingly, the once-daily ...

Arvinas and Pfizer received approval from the Food and Drug Administration for Veppanu, the companies' jointly developed advanced breast cancer treatment. Arvinas said Friday the FDA approved the drug ...

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has granted approval for Pfizer Inc (NYSE:PFE) and Arvinas Inc ...

The health news this week highlights key legal and medical developments. Danco Laboratories is challenging a court's decision ...

Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- ...